Analyst Price Targets — IRWD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 3:35 pm | Amy Li | Jefferies | $3.70 | $3.60 | StreetInsider | Ironwood Pharmaceuticals (IRWD) PT Raised to $3.70 at Jefferies |
| January 5, 2026 12:27 pm | — | Craig-Hallum | $5.70 | $4.27 | TheFly | Craig-Hallum upgrades Ironwood to Buy following 2026 guidance |
| January 4, 2026 11:22 pm | — | Wells Fargo | $5.00 | $4.27 | TheFly | Ironwood price target raised to $5 from $3 at Wells Fargo |
| November 26, 2025 3:07 pm | — | Craig-Hallum | $3.80 | $3.83 | TheFly | Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum |
| April 14, 2025 3:30 pm | Faisal Khurshid | Leerink Partners | $1.00 | $0.65 | TheFly | Ironwood price target lowered to $1 from $3 at Leerink |
| January 31, 2025 12:05 pm | Mohit Bansal | Wells Fargo | $7.00 | $2.34 | TheFly | Ironwood price target lowered to $7 from $12 at Wells Fargo |
| September 9, 2024 6:26 am | Faisal Khurshid | Leerink Partners | $5.00 | $4.51 | TheFly | Ironwood initiated with a Market Perform at Leerink |
| August 9, 2024 8:24 am | Mohit Bansal | Wells Fargo | $12.00 | $4.05 | TheFly | Ironwood price target lowered to $12 from $14 at Wells Fargo |
| May 22, 2024 7:47 am | David Amsellem | Piper Sandler | $18.00 | $6.82 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD) |
| May 22, 2024 5:13 am | Mohit Bansal | Wells Fargo | $14.00 | $6.78 | StreetInsider | Wells Fargo Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD) |
Latest News for IRWD
Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.
IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript
Ironwood Pharmaceuticals NASDAQ: IRWD reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, prompting the company to raise its full-year 2026 financial outlook.
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.14 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRWD.
U.S. House Trading
No House trades found for IRWD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.